All Press Releases for April 11, 2023

Dr. Suchismita Acharya Celebrated for Dedication and Innovation to the Pharmaceutical Industry

Suchismita Acharya, PhD lends years of pharmaceutical experience to her work with AyuVis Research

    FORT WORTH, TX, April 11, 2023 /24-7PressRelease/ -- Suchismita Acharya has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Drawing on more than 20 years of pharmaceutical experience in small-molecule drug discovery and development, Dr. Acharya presently excels as the Founder and Chief Executive Officer of AyuVis Research, Inc., which is developing a wide range of pharmaceutical therapies aimed at increasing patient survival and quality of life by fighting inflammation and infection. Through AyuVis, she has focused on a number of key therapeutic areas, including a chronic lung disease, bronchopulmonary dysplasia, lung infection, acute lung injury, sepsis and retinopathy. As Chief Executive Officer, she oversees the identification, screening, and development of small molecule immunotherapies that have proven to be non-toxic in preclinical testing and are based on a naturally occurring carbohydrate. Alongside her executive role with AyuVis, Dr. Acharya is an Assistant Professor at the University of North Texas Health Science Center (UNTHSC) in the Department of Pharmacology & Neuroscience and North Texas Eye Research Institute where she leads drug design, synthesis and development for glaucomatous optic neuropathy, AMD, diabetic retinopathy, and other neurodegenerative diseases. Due to her vast breadth of professional knowledge, she also served as an expert for YourEncore, where she reviews and analyzes SAR and pre-clinical data, and assesses drug properties.

During the early stages of her career, Dr. Acharya gained valuable expertise in drug design and development as a Project Manager with Alcon Labs and Novartis. Following her career in industry, she began her journey working in academia as a Faculty Associate and Research Adjunct Lecturer for the University of Arlington. Driven to remain abreast of changes in the field, Dr. Acharya aligns herself with the Small Business Association and the Association for Research in Vision and Ophthalmology. An expert in her field, Dr. Acharya holds a Master of Science in Chemistry from Utkal University and a PhD in Organic Chemistry from the Indian Institute of Chemical Technology. Likewise, she completed postdoctoral studies in Organic and Medicinal Chemistry from the University of Texas Southwestern Medical Center.

Throughout her career, she has obtained several patents for antimicrobial carboline compounds, Bradykinin receptor agonists and their use in the treatment of ocular hypertension, and the preparation of aryl and heteroaryl tetrahydrobenzazepine derivatives as 5-HT agonists and their use in glaucoma treatments as well as for immunomodulatory compounds for AyuVis. Along with other industry scholars, she has also co-authored 30+ peer reviewed research articles in the Journals and authored two book chapters.

In 2013, Dr. Acharya "packed up" her arsenal of drug discovery and development experience from Alcon and Novartis to begin her journey of searching for the right project to start her own venture. Around this same time a paper was published on how a parasitic infection protected the host from bacterial infection and inflammation, and uncovered a molecule produced by the parasite responsible for this protective effect, chitohexaose. As a medicinal chemist and pharmaceutical scientist, Dr. Acharya saw an opportunity to create a new class of drugs and founded AyuVis in 2014.

Her goal was to design small molecule analogs that would preserve and enhance its beneficial therapeutic properties and safety profile, while simultaneously being optimized for pharmaceutical manufacturing and clinical use. The result is AyuVis' series of novel compounds which produce an anti-inflammatory and antimicrobial activation of white blood cells to prevent and treat a broad spectrum of diseases with huge unmet medical need with a cumulative $100B+ market potential.

The first indication AyuVis is targeting is the prevention of chronic lung injury in preterm babies, called bronchopulmonary dysplasia, for which the lead compound has been granted Orphan Drug and Rare Pediatric Disease Designations by the US FDA. AyuVis has published five peer-reviewed papers in international scientific journals and has two patents granted in the US and several countries and two more patents pending. Today, an Investigational New Drug (IND) application is in preparation for the lead compound to soon enter First-in-Human clinical testing. AyuVis' goal is to save and improve the lives of millions where there is high unmet medical need, starting first in preterm babies and expanding to address more pediatric and adult diseases.

In light of her outstanding body of work, Dr. Acharya has been recognized on several occasions, earning a National Merit Scholarship to Utkal University, a Graduate Research Fellowship through the Indian government's Council of Scientific and Industrial Research, a postdoctoral fellowship through the National Institutes of Health, one of four leading "Pharma Pioneers" in DFW by D CEO Magazine, a "Technical Knockout" by Fort Worth Inc. Magazine, Fort Worth Inc. "Top 400" in 2023, Rising Star Awards from BioNorthTX and separately TechFW, Defense Innovation Technology Challenge Winner from Tech Connect (US Department of Defense), and the Novartis Spotlight award. While her career has been filled with standout moments, she takes the most pride in her work with Novartis, where she helped to discover a particular drug's mechanism of action. The cornerstone of her overall success lay in her open-minded nature and her wonderful mentors. Looking toward the future, Dr. Acharya aims to expand AyuVis and eventually hire and train more individuals with similar visions to give back to the scientific community.

For more information on AyuVis or Dr. Acharya, contact Sarah Wright at [email protected], follow the company LinkedIn page for updates, or visit

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Marquis celebrates its 125th anniversary in 2023, and Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who's Who® website at

# # #

Contact Information

-- --
Marquis Who's Who Ventures LLC
Uniondale, NY
Voice: 844-394-6946
E-Mail: Email Us Here
Website: Visit Our Website
Follow Us: